Navigation Links
Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
Date:3/6/2008

Opens Facility to Support European Partnerships

ALAMEDA, Calif., and PARIS, March 6 /PRNewswire/ -- Singulex Inc. announced today a collaboration with Novartis Pharma AG to give Novartis access to Singulex's advanced biomarker detection technology through an Erenna(TM) Technology Access Program (ETAP). Terms of the collaboration were not disclosed. In addition, the company announced the opening of a facility in Paris, France to support the needs of Singulex's collaborators in Europe.

"We have gained tremendous traction with potential pharmaceutical partners in the last year," said Philippe Goix, Ph.D., president and CEO of Singulex. "Establishing this relationship with Novartis further validates the power of our technology in therapeutic efficacy and toxicity programs."

As part of its ETAP partnership with Novartis, Singulex has placed its flagship biomarker detection platform, the Erenna system, at Novartis' Basel, Switzerland facility and will be working with Novartis to develop biomarker assays that have the potential to advance Novartis' drug development programs. Erenna and accompanying assays are designed to measure very low levels and small changes of protein biomarkers across a variety of biological samples from multiple species.

"Among our goals is the establishment of strong collaborations with pharmaceutical companies that will bring advanced technologies to their translational medicine and biomarker programs," continued Goix. "By opening a facility in Europe, we are bringing our strong immunoassay development skills and Erenna technology closer to European partners. We are actively working to expand our footprint across the globe, and this facility does just that."

About Singulex

Singulex develops and commercializes innovative technology solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex develops customized biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers in a variety of biological samples with extreme sensitivity and accuracy. Singulex is currently conducting several pilot studies with academic and molecular diagnostic partners to validate the company's commercial digital molecule detection platform, the Erenna(TM) Immunoassay System. Singulex's research and development facilities are located at the Center for Emerging Technologies in St Louis, Missouri, and the company's commercial operations are based in Alameda, California. To learn more about Singulex, please visit us at http://www.singulex.com.

About ETAP

The Erenna(TM) Technology Access Program (ETAP) offers select clients the opportunity to use Singulex's flagship Erenna system to improve and validate their vital immunoassays, adding as much as 1-3 logs of improvement in sensitivity and providing less than 20% coefficient of variability. ETAP includes the Erenna system, which is designed to detect and count single molecules, customized immunoassay development services, reagents, software and direct and personal client service.


'/>"/>
SOURCE Singulex Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
2. GeneGo Collaborates With The Netherlands Toxicogenomics Center on $100 Million Grant
3. NIH collaborates with EPA to improve the safety testing of chemicals
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
6. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
7. New technique producing small things in large quantities
8. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
9. Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India
10. Researchers outline structure of largest nonvirus particle ever crystallized
11. China-Biotics, Inc. Receives Approval to Begin Construction on Large-Scale Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):